New drug combo shows promise for untreatable liver cancer in early trial
NCT ID NCT07543783
First seen Apr 28, 2026 · Last updated Jun 09, 2026 · Updated 8 times
Summary
This study tests a new treatment for people with advanced liver cancer that cannot be removed by surgery. The treatment combines two drugs (low-dose bevacizumab and adebrelimab) with a procedure that delivers chemotherapy directly to the liver (TACE-HAIC). The goal is to see if this combination can shrink tumors and control the disease. About 38 participants will be enrolled in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.